Fermé C - Search Results

1

Challenges and perspectives in the immunotherapy of Hodgkin lymphoma.

Michot JM, Lazarovici J, Ghez D, Danu A, Fermé C, Bigorgne A, Ribrag V, Marabelle A, Aspeslagh S. Michot JM, et al. Among authors: ferme c. Eur J Cancer. 2017 Nov;85:67-77. doi: 10.1016/j.ejca.2017.08.014. Epub 2017 Sep 9. Eur J Cancer. 2017. PMID: 28892775 Review.

2

[the role of radiotherapy for limited stage Hodgkin's disease in 1999: limitations and perspectives].

Cosset JM, Fermé C, Henry-Amar M, Carde P. Cosset JM, et al. Among authors: ferme c. Cancer Radiother. 1999 Mar-Apr;3(2):112-8. doi: 10.1016/s1278-3218(99)80041-9. Cancer Radiother. 1999. PMID: 10230370 Clinical Trial. French.

3

Hodgkin's disease primarily involving the oropharynx: case report and review of the literature.

Aloulou S, Farhat H, Bosq J, Vanel D, Ribrag V, Turhan AG, Girinsky T, Fermé C. Aloulou S, et al. Among authors: ferme c. Hematol J. 2002;3(3):164-7. doi: 10.1038/sj.thj.6200166. Hematol J. 2002. PMID: 12111654 Review.

4

Phase II trial of irinotecan (CPT-11) in relapsed or refractory non-Hodgkin's lymphomas.

Ribrag V, Koscielny S, Vantelon JM, Fermé C, Rideller K, Carde P, Bourhis JH, Munck JN. Ribrag V, et al. Among authors: ferme c. Leuk Lymphoma. 2003 Sep;44(9):1529-33. doi: 10.3109/10428190309178775. Leuk Lymphoma. 2003. PMID: 14565655 Clinical Trial.

5

Outcome of elderly patients with aggressive Non-Hodgkin's lymphoma refractory to or relapsing after first-line CHOP or CHOP-like chemotherapy: a low probability of cure.

Jabbour E, Chalhoub B, Suzan F, Aloulou S, Cainap C, Toumi N, Fermé C, Carde P, Ribrag V. Jabbour E, et al. Among authors: ferme c. Leuk Lymphoma. 2004 Jul;45(7):1391-4. doi: 10.1080/10428190310001653736. Leuk Lymphoma. 2004. PMID: 15359638 Review.

6

Phase II study of concomitant chemoradiotherapy in bulky refractory or chemoresistant relapsed lymphomas.

Girinsky T, Lapusan S, Ribrag V, Koscielny S, Ferme C, Carde P. Girinsky T, et al. Among authors: ferme c. Int J Radiat Oncol Biol Phys. 2005 Feb 1;61(2):476-9. doi: 10.1016/j.ijrobp.2004.06.210. Int J Radiat Oncol Biol Phys. 2005. PMID: 15667970 Clinical Trial.

7

Prognostic value of the age-adjusted International Prognostic Index in chemosensitive recurrent or refractory non-Hodgkin's lymphomas treated with high-dose BEAM therapy and autologous stem cell transplantation.

Jabbour E, Peslin N, Arnaud P, Ferme C, Carde P, Vantelon JM, Bocaccio C, Bourhis JH, Koscielny S, Ribrag V. Jabbour E, et al. Among authors: ferme c. Leuk Lymphoma. 2005 Jun;46(6):861-7. doi: 10.1080/10428190500054350. Leuk Lymphoma. 2005. PMID: 16019530

8

Role of imaging to choose treatment.

Fermé C, Vanel D, Ribrag V, Girinski T. Fermé C, et al. Cancer Imaging. 2005 Nov 23;5 Spec No A(Spec No A):S113-9. doi: 10.1102/1470-7330.2005.0032. Cancer Imaging. 2005. PMID: 16361126 Free PMC article.

9

High survival rate with the LMT-89 regimen in lymphoblastic lymphoma (LL), but not in T-cell acute lymphoblastic leukemia (T-ALL).

Jabbour E, Koscielny S, Sebban C, Peslin N, Patte C, Gargi T, Biron P, Fermé C, Bourhis JH, Vantelon JM, Arnaud P, Ribrag V. Jabbour E, et al. Among authors: ferme c. Leukemia. 2006 May;20(5):814-9. doi: 10.1038/sj.leu.2404156. Leukemia. 2006. PMID: 16511514 Clinical Trial.

10

Prospective study of bone marrow infiltration in aggressive lymphoma by three independent methods: whole-body MRI, PET/CT and bone marrow biopsy.

Ribrag V, Vanel D, Leboulleux S, Lumbroso J, Couanet D, Bonniaud G, Aupérin A, Masson F, Bosq J, Edeline V, Fermé C, Pigneur F, Schlumberger M. Ribrag V, et al. Among authors: ferme c. Eur J Radiol. 2008 May;66(2):325-31. doi: 10.1016/j.ejrad.2007.06.014. Epub 2007 Jul 24. Eur J Radiol. 2008. PMID: 17651934

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

134 results

Search Page